- Home
- RARE vs NN Comparison
RARE vs NN Comparison
Compare RARE & NN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | NN |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RARE | NN |
|---|---|---|
| Price | $12.92 | $15.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $59.10 | $25.00 |
| AVG Volume (30 Days) | ★ 3.8M | 2.1M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | $4,573,000.00 |
| Revenue This Year | $13.12 | N/A |
| Revenue Next Year | $37.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $13.81 | $10.87 |
| 52 Week High | $39.89 | $24.42 |
Technical Indicators
Market Signals| Indicator | RARE | NN |
|---|---|---|
| Relative Strength Index (RSI) | 19.69 | 47.87 |
| Support Level | N/A | $15.51 |
| Resistance Level | $26.56 | $17.59 |
| Average True Range (ATR) | 0.91 | 0.80 |
| MACD | -1.07 | -0.11 |
| Stochastic Oscillator | 0.08 | 60.36 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.